DENVER, May 20, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) ("DaVita") announced today the upsize and pricing of its previously announced private offering (the "offering") of its 6.750% senior notes due 2033 (the "2033 notes"). The aggregate principal amount of the 2033 notes offered in the offering was increased from $750 million to $1 billion, and the 2033 notes were priced at 100.000% of their face amount to yield a 6.750% coupon. The offering is expected to close on May 23, 2025, subject to satisfactio ...

Captures key initiatives achieved in 2024, driving 2025 ESG goalsDENVER, May 20, 2025 /PRNewswire/ -- Today, DaVita (NYSE: DVA) published its Community Care report, underpinning its long-standing commitment to corporate citizenship and highlighting strides made towards ambitious Environmental, Social and Governance (ESG) goals set to be achieved this year. Milestones and achievements reflect calendar year 2024.In 2021, DaVita announced broadened ESG goals and has since reported progress against its five str ...

DENVER, May 20, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) ("DaVita") announced today that it has commenced a private offering (the "offering") of $750 million aggregate principal amount of its senior notes due 2033 (the "2033 notes"), subject to market and other conditions.DaVita intends to use the net proceeds from the offering (i) to repay outstanding revolving credit facility borrowings, together with related accrued and unpaid interest thereon, (ii) to pay any costs, fees and expenses in connection w ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Sc ...

DaVita Inc. (DVA) delivered adjusted earnings per share (EPS) of $2.00 in the first quarter of 2025, down 11.5% year over year. However, the figure surpassed the Zacks Consensus Estimate by 14.3%.GAAP EPS for the quarter was $2.00, reflecting a plunge of 24.5% year over year.DaVita’s Revenues in DetailRevenues of $3.22 billion in the first quarter increased 4.9% year over year. The figure topped the Zacks Consensus Estimate by 0.4%.Revenue per treatment in the first quarter of 2025 was $400.1 million, up 4. ...

DaVita HealthCare (DVA) came out with quarterly earnings of $2 per share, beating the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $2.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 14.29%. A quarter ago, it was expected that this kidney dialysis provider would post earnings of $2.21 per share when it actually produced earnings of $2.24, delivering a surprise of 1.36%.Over the last four quarters ...

Financial Data and Key Metrics Changes - First quarter adjusted operating income was $439 million, adjusted EPS was $2, and free cash flow was negative $45 million, with adjusted operating income above previous guidance due to strong expense management and international performance [18][25] - Revenue per treatment increased by $4, with approximately $10 attributed to new reimbursement for phosphate binders, partially offset by a $5 decline due to seasonal patient responsibility [21][39] - Patient care cost per treatment increased by $7 sequentially, driven by approximately $8 per treatment of new costs associated with phosphate binders [21] Business Line Data and Key Metrics Changes - Adjusted international operating income increased by $29 million compared to the fourth quarter, with strong performance across various markets [22] - Integrated Kidney Care (IKC) reported operating losses of $29 million, in line with expectations, with seasonally stronger performance anticipated in the second half of the year [22] Market Data and Key Metrics Changes - Treatments per day declined by 40 basis points compared to Q1 2024, primarily due to a higher missed treatment rate caused by a severe flu season [19] - The company expects an approximately 50 basis point decline in treatments for the year, influenced by flu-related impacts and a cyber incident [20] Company Strategy and Development Direction - The company remains committed to investing available capital in innovation and high-return growth opportunities, including a recent acquisition in Latin America [13] - The capital allocation strategy includes returning capital to shareholders through share repurchases, with approximately $680 million repurchased since the last earnings call [13] Management's Comments on Operating Environment and Future Outlook - Management highlighted the resilience of operations despite a cybersecurity incident that disrupted parts of the business, with uninterrupted patient care maintained [9][10] - The company reiterated its 2025 guidance range for adjusted operating income and adjusted EPS, despite headwinds from the cyber incident and a challenging flu season [16][25] Other Important Information - The company launched a community-based collaboration with the YMCA to support chronic kidney disease education and prevention, with early results showing 30% of participants screened had previously undiagnosed CKD [6][7] - The majority of costs related to the cyber incident are expected to be one-time items recognized in the second quarter [31] Q&A Session Summary Question: Impact of flu and cyber attack on treatment growth - Management indicated that the flu had a more significant impact on the full year guidance, with the census decline in Q1 affecting the full year [29] Question: Costs related to the cyber attack - Management clarified that some costs will be direct and non-GAAP, likely covered by insurance, while others will flow through the P&L and are included in guidance [31] Question: Phosphate binders uptake and drug mix - The mix leaned towards iron-based binders, leading to an adjustment in guidance to the upper end of the previous range [33] Question: Revenue per treatment and managed care increases - Management confirmed that revenue per treatment guidance remains unchanged, with increases expected from both core business and oral medications [42] Question: IKC patient treatment and competitive pricing - Management noted that the financials are playing out as expected, with a disciplined approach to patient care and financial modeling despite competitive pressures [51] Question: International performance outlook - International operations had a strong quarter, with positive contributions from various markets and a successful acquisition [57]

DaVita (DVA) Q1 2025 Earnings Call May 12, 2025 05:00 PM ET Speaker0 evening. My name is Michelle, and I will be your conference facilitator today. At this time, I would like to welcome everyone to the DaVita First Quarter twenty twenty five Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer period. Mr. Eliason, you may begin your conference, sir. Speaker1 Thank you, and welcome to our first quarter conference c ...

For the transition period from ___________ to ___________ Commission File Number: 1-14106 DAVITA INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 51-0354549 (State of incorporation) (I.R.S. Employer Identification No.) 2000 16th Street ...

"Our strong first quarter performance demonstrates the stability and consistency of our operating model" said Javier Rodriguez, CEO of DaVita Inc. "We maintain a steadfast commitment to being the provider, employer and partner of choice and returning value to our shareholders." Financial and operating highlights for the quarter ended March 31, 2025: | | Three months ended | | | | | | | --- | --- | --- | --- | --- | --- | --- | | | March 31, 2025 December 31, 2024 | | | | | March 31, 2024 | | Net income attr ...